Precision Medicine

Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
RSS icon

Google's Verily to collect health data from 10,000 for long-range study

Verily, formerly Google Life Sciences, plans on enrolling 10,000 participants in a study incorporating the latest technology for data collection on how individuals can lead their healthiest lives.

First Published Clinical Study Successfully Uses Precision Medicine To Predict Prescription Opioid Abuse

As a Bronze Sponsor of the National Rx Drug Abuse and Heroin Summit, Proove® Biosciences, Inc. announces the first-ever peer-reviewed published clinical study analyzing genetics, environmental, and lifestyle factors to accurately predict prescription opioid abuse.

FDA Releases gammaCore, the First Non-Invasive Vagus Nerve Stimulation Therapy Applied at the Neck for Acute Treatment of Pain Associated with Episodic Cluster Headache in Adult Patients

electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, announced today that the U.S. Food and Drug Administration (FDA) released the use of gammaCore® (non-invasive vagus nerve stimulator) for the acute treatment of pain associated with episodic cluster headache in adult patients. gammaCore transmits a mild electrical stimulation to the vagus nerve through the skin, resulting in a reduction of pain. This is the first FDA product release for electroCore in the U.S.

Alphabet introduces wearable for continuous data collection

Verily, a subsidiary of Alphabet, recently introduced its newly developed Verily Study Watch. This wearable was made more for the clinical research rather than the consumer and offers continuous monitoring, making collecting data as easy as ever.

Thumbnail

mHealth improves HIV patient engagement, access to care

A study, published in Mobile Media & Communication, found mobile health interventions (mHealth) improve access to care and patient engagement in patients with HIV.

Noom’s diabetes prevention program recognized by the CDC

The Centers for Disease Control and Prevention (CDC) has officially recognized virtual diabetes prevention program (DPP) developed by Noom. First introduced in 2013, the program was submitted for recognition when the CDC began accepting mobile and online DPP applications in 2015.

Telemedicine effective in assessing coma patients

Improving access to care in critically ill patients is a major factor in earlier treatment, and telemedicine could be the best option. A recent study, published in Telemedicine and e-Health, found telemedicine to be an effective tool in evaluating level on consciousness (LOC) in coma patients. 

Thumbnail

ACO success limited by high turnover among physicians, patients

The effectiveness of accountable care organizations (ACOs) may be limited by two factors, according to a new study published in Health Affairs: low numbers of enrollees attributed to participating physicians and the constant “churn” of the patient population caused by substantial physician turnover.

Displaying 1977 - 1984 of 3584

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup